key: cord-0329737-6ie0lqi4 authors: Edwards, H. B.; Redaniel, T.; Sillero-Rejon, C.; Margelyte, R.; Peters, T. J.; Tilling, K.; Hollingworth, W.; McLeod, H.; Craggs, P.; Hill, L.; Redwood, S.; Donovan, J. L.; Treloar, E.; Wetz, E.; Swinscoe, N.; Ford, G. A.; MacLeod, J. A.; Luyt, K. title: National PReCePT Programme: a quasi-experimental before-and-after evaluation of the implementation of a national quality improvement programme to increase the uptake of magnesium sulphate in pre-term deliveries date: 2022-05-23 journal: nan DOI: 10.1101/2022.05.20.22275353 sha: dcaa2c5a2e94e0c186f24a221f2a2b363dbb2928 doc_id: 329737 cord_uid: 6ie0lqi4 Objective: To evaluate the effectiveness and cost-effectiveness of the National PreCePT Programme (NPP) in increasing magnesium sulphate (MgSO4) in pre-term births. Design: A quasi-experimental before-and-after design Setting: Maternity units within NHS England and the AHSN network in 2018. Participants: Maternity units in England (n=137) who participated in the NPP. Interventions: NPP support which included the PReCePT QI toolkit and materials (pre-term labour proforma, staff training presentations, parent leaflet, posters for the unit, learning log), regional AHSN level support, and up to 90 hours funded backfill for a midwife champion to lead implementation. Main outcome measures: MgSO4 post-implementation uptake compared to pre-implementation uptake. Implementation and lifetime costs were estimated. Results: Compared to pre-implementation estimates, the average MgSO4 uptake in 137 maternity units in England increased by 6.3 percentage points (95% CI 2.6 to 10.0 percentage points) to 83.1% post-implementation, accounting for unit size, maternal, baby, and maternity unit factors, time trends, and AHSN. Further adjustment for early or late initiation of NPP activities increased the estimate to 9.5 percentage points (95% CI 4.3 to 14.7 percentage points). From a societal and lifetime perspective, the health gains and cost-savings associated with the NPP effectiveness generated a net monetary benefit of 866 GBP per preterm baby and the probability of the NPP being cost-effective was greater than 95%. Conclusion: This national QI programme was effective and cost-effective. National programmes delivered via coordinated regional clinical networks can accelerate uptake of evidence-based therapies in perinatal care. Since 2015 the UK National Institute for Health and Care Excellence (NICE) has recommended administration of Magnesium Sulphate (MgSO 4 ) for fetal neuroprotection in very preterm deliveries as a core part of maternity care. By 2017, only two-thirds of all eligible women in England were being given MgSO 4 , with wide regional variation. The PReCePT pilot study showed an increase in uptake from 21% (2012-2013) to 88% after the introduction of the tool in2015 in 5 units. The National PReCePT Programme (NPP) was rolled out in 2018 by the national network of Academic Health Science Networks with a target to increase MgSO 4 administration in England to 85% by 2020. The study has shown that the nationwide implementation of the NPP, which provided a Quality Improvement (QI) toolkit and materials, cross unit AHSN regional level support, and funded backfill for a unit midwife 'champion' through local regional support was effective and cost-effective. Scaling-up of network supported QI programmes at national level can accelerate uptake of new therapies and promote improvements in perinatal care delivery. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint Around 10% of very preterm births in developed countries result in Cerebral Palsy (CP), [1] [2] [3] representing a significant burden for affected individuals and families, 4 and costs for healthcare services. Antenatal magnesium sulphate (MgSO 4 ) reduces the risk of CP in the child by around 30% when given to women at risk of preterm birth, 5 and around 200 cases of CP in England could be avoided by consistent administration of MgSO 4 during labour each year. 6 Administration of MgSO4 can be highly cost-effective with an estimated £1M lifetime societal savings per case of CP averted. 7, 8 Since 2015 the UK National Institute for Health and Care Excellence (NICE) has recommended administration of MgSO 4 in very preterm deliveries as a core part of maternity care. 9 Yet, by 2017 only 64% of eligible women were receiving MgSO 4 . 10 High regional variation in uptake (range 49% to 78%) indicated inequalities in perinatal care. 10 The PReCePT (Preventing Cerebral Palsy in Pre Term labour) Quality Improvement (QI) toolkit and approach was developed to improve maternity staff awareness and thereby increase use of MgSO 4 , and the pilot study (five maternity units) showed an increase in uptake from 21% to 88% after the completion of the pilot. 11 In 2018, NHS England funded the National PReCePT Programme (NPP), with units receiving implementation support provided regionally through the 15 Academic Health Science Networks (AHSNs), with the aim of increasing MgSO 4 use in England to 85% by 2020. In the NPP, the PReCePT QI toolkit and other materials (pre-term labour proforma, staff training presentations, parent information leaflet, posters for the unit, and a learning log) 12 were provided to each participating unit (see supplementatry file -National PReCePT Programme provisions). Each unit appointed a lead midwife to be their 'PReCePT champion', and the NPP provided up to 90 hours funded backfill for this role. AHSN level coaching and support via a clinical lead (obstetrician and/or neonatologist) was also available to each unit and champion. Additional support was provided by the AHSN Network NPP steering group and the national Clinical Lead and Programme Manager, and through shared learning events between AHSN managers leading the NPP in their area. The NPP was launched in two tranches of maternity units, in May and September 2018. A cluster randomised trial to determine the effectiveness of an enhanced support QI programme (ESP) was conducted alongside the NPP implementation comparing uptake in 13 ESP units and 27 control units implementing the NPP. 13, 14 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) In this study we evaluated the effectiveness and cost-effectiveness 15 of the NPP in increasing MgSO 4 uptake. We hypothesised that the implementation of the NPP would help increase MgSO 4 uptake beyond the expected increase due to the underlying trend rate. The evaluation followed a quasi-experimental before-and-after design, comparing absolute difference in mean MgSO 4 uptake between the 12 months pre-implementation and 12 months post-implementation periods, adjusted for possible confounders. The month of the initiation of the NPP in the maternity unit (adoption date) was excluded from the analysis. We used anonymised patient-level data from the UK National Neonatal Research Database (NNRD). 16 The database collates information from electronic patient records of neonatal units who are part of the UK National Neonatal Collaborative. Data collected include mother and baby socio-demographic characteristics, clinical information and data on MgSO 4 use. All data in the NNRD undergoes multiple quality assurance procedures and is considered to have high accuracy and completeness. 16, 17 Fields relating to the MgSO 4 care pathway are regarded as good quality (over 70% completeness). Estimated NPP adoption dates for each unit, demarcating the two periods, were provided by the AHSNs. This was defined as the date when the unit had initiated an implementation plan and patients started benefitting from the Programme. Pre-and post-implementation periods covered between October 2017 and June 2020. In the effectiveness analysis, for consistency with nationally reported data (National Neonatal Audit Programme (NNAP) reporting), MgSO 4 uptake was defined as the number of mothers recorded as receiving MgSO 4 divided by the total number of eligible mothers, excluding missing values from the denominator. This was expressed as a percentage and computed per month per unit. For the cost-effectiveness analysis, missing MgSO 4 uptake was considered as 'not given' and included in the denominator. We only included data on singletons and one baby (the first born) from each multiple birth. All babies in multiple births with an NNRD record were included in descriptions of baby-level demographics. In cases where only one baby had a record for MgSO 4 , we recoded the missing MgSO 4 status of the other multiples to match that for their twin/triplet who did have a record. For multiples with conflicting records (e.g. Baby1=given, Baby2=not given), we recorded MgSO 4 uptake as having been given. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Possible confounding factors adjusted for in the study included variables at three levels: the baby, mother and maternity unit. Characteristics of the baby were: birthweight (grams) adjusted for gestational age (weeks) and sex, expressed as a z-score; and whether the baby For the effectiveness analysis, all baby and mother characteristics were aggregated to the level of the maternity unit (using non-missing information) per study month as follows: mean z-score for gestational age adjusted for birthweight, proportion of multiple births of all eligible births, mean maternal age, proportion of mothers who identify as of white ethnicity, mean IMD decile, proportion of mothers who had pregnancy hypertension. Missing information was minimal, with the exception of mother's ethnicity (supplementary file -Missing data on possible confounders). The cost-effectiveness analysis used baby-level data, and missing data on possible confounders were imputed through chained equations. 18 To compare the difference in mean monthly MgSO 4 uptake between the pre-and postimplementation periods, we conducted a multi-level mixed-effects linear regression using the maternity unit as the primary level of analysis. The mean MgSO 4 uptake was modelled directly; the model was weighted on unit size (number of eligible mothers at each unit) and adjusted for clustering by AHSN (secondary level of analysis). The model was adjusted for all known potential confounders. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint To take into account NPP activities prior to the reported NPP implementation dates (as units were reported to have started with some activities before or after the adoption month), weexcluded records within three months either side of the NPP adoption month. As sensitivity analyses, we also looked at the effect of the following on the difference in mean monthly MgSO 4 uptake between the two NPP periods: (1) including the 13 PReCePT ESP trial units that received the enhanced QI support programme (NPP plus unit-level coaching, an additional 90 hours backfill funding for the local midwife champion and approximately 104 hours of funded backfill for the unit obstetrician/neonatologist lead); 13 and (2) excluding units in one AHSN that started adoption three months later than other AHSNs. The mean implementation cost per unit of the NPP was estimated from data supplied by the national programme team. NPP costs included those relating to national programme management, funded support from AHSNs, and the funded backfill of clinical time for midwives and regional clinical leads. The mean implementation cost per baby was calculated as the mean implementation cost per unit divided by the total number of babies per unit eligible for MgSO 4 treatment delivered during the 12-month follow-up period. In a decision tree analysis, we estimated the net monetary benefit of the NPP using a lifetime horizon and societal perspective. Model parameters were based on NNRD data for MgSO 4 uptake, and reported estimates for lifetime gains in quality-adjusted life-years (QALYs) and societal cost savings as a consequence of preventing CP via MgSO 4 treatment. 19 All cost estimates were converted to Pounds Sterling and inflated to 2019 prices (supplementary file -Estimated lifetime costs and QALYs per patient associated with MgSO4 treatment). Babies delivered by caesarean section were defined as imminent births (those certain to occur within 24 hours) and all other babies as threatened. Our deterministic analysis used a willingnessto-pay threshold of £20,000 per QALY gained, in line with the relevant NICE guidance. 20 To estimate the model parameter associated with MgSO 4 uptake differences between the baseline and follow-up periods, we conducted a multi-level mixed-effects linear logistic regression at the baby level, adjusted for clustering by AHSN and unit. The model was also adjusted for all listed confounders, including type of birth and interaction between type of birth and pre-and post-implementation, entered into the model simultaneously. We conducted a probabilistic analysis using Monte Carlo simulation with 10,000 samples drawn from the parameter distributions. For lifetime costs and health utilities estimates, we used the incremental differences. Point estimates, probabilistic distribution assumptions, and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint parameter source estimates are reported in appendix p 10. Incremental costs and effects were plotted on the cost-effectiveness plane and a cost-effectiveness acceptability curve plotted for willingness-to-pay thresholds from zero to £100,000 per QALY gained. In a subgroup analysis, we explored differences in cost-effectiveness between the type of maternity unit (SCU/HDU or NICU). Of the 155 maternity units in England, a total of 150 participated in the NPP. The five units that did not participate were pilot sites for the PReCePT QI toolkit development 11 preterm births per unit per month. Maternal and baby characteristics were similar between the pre-implementation 12 months and post-implementation 12 months (Table 1 ). The average MgSO 4 uptake across all units in the 12-month pre-implementation period was 70.9, increasing to 83.1% across the 12-month post-implementation period ( Table 2 ). The average amount of missing MgSO 4 data dropped from 2.9% to 1.4% across the comparison periods. Imminent delivery was the most common reason for why MgSO 4 was not given (62.1% preimplementation and 75.4% post-implementation). Pre-implementation, MgSO 4 was recorded as 'not offered' in 16.1% of cases and post-implementation this had dropped to 11.4% (Table 2) . Overall, the trend in mean MgSO 4 uptake increased steadily ( Figure 1 , supplementatry file -MgSO 4 uptake through time) from October 2017 (earliest pre-implementation date) to June 2020 (the latest follow-up date). Average MgSO 4 uptake varied by AHSN, and within each AHSN, high monthly variation in uptake was observed (supplementatry file -MgSO4 uptake by AHSN). The lowest average uptake was around 65% at the end of 2017, and the highest was around 94% around May 2020. The unadjusted average increase in uptake between the pre-and post-implementation periods was 12.2 percentage points. After adjusting for unit size, clustering by AHSN, maternal, baby, and maternity unit factors, and time, the average increase in uptake between the pre-and post-implementation periods was 6.3 percentage points (95% CI 2.6 to 10.0 percentage points, p<0.001) ( Table 3) . After taking into account the likely variation in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint activities around the NPP adoption month (by removing from the analysis data for 3 months before and after the adoption date), the estimate changed to 9.5% (95% CI 4.3 to 14.7%, p<0.001) ( Table 3) . Neither including the PReCePT RCT study units nor excluding units from the one AHSN that started later than the others from the analysis had any substantial effect on the difference in uptake between pre-to post-implementation periods. The proportion of missing MgSO 4 data fluctuated during the NPP period between 0-7%, but overall tended to decrease over time (supplementary file -Trend in missing MgSO 4 data over time). Around April 2020, at the start of the Covid pandemic, there appeared to be an increase in the amount of missing MgSO 4 data. The mean funded implementation cost of the NPP was £6,044 per unit, £738 relating to national programme management, £2,764 funded support from AHSNs, and £2,500 funded backfill of clinical time for midwives. The mean implementation cost per baby was £267 per preterm baby born. The incremental impact of the NPP on uptake of MgSO 4 during the 12 months follow-up was an absolute increase of 6.0 percentage points (95% CI 4.6% to 10.9%, p=0.03). From a societal perspective, the NPP was associated with a mean increase of 0.01 QALYs per preterm baby and £649 total incremental savings over a baby's lifetime. This equates to a net monetary benefit of £886 per preterm baby exposed to MgSO4 at a willingness-to-pay threshold of £20,000, and the probability of the NPP being cost-effective was greater than 95% (Table 4 ; supplementary file -Cost-effectiveness plane of National PreCePT Programme). Although the NPP implementation cost per preterm baby was higher in small (SCU/HDU) units than the larger NICU units (Table 4) , the probability of the NPP being cost-effective in small units was still high, at about 85% (supplementary file -Cost-effectiveness plane of National PreCePT Programme). To our knowledge, this is the first evaluation of the impact of the implementation of a national perinatal QI programme focused on increasing administration of an evidence-based drug . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study made use of routinely collected maternal and neonatal data from the NNRD and the NPP, providing robust, objective and high-quality data for the evaluation. This enabled the evaluation to cover all maternity units in England with minimal costs, making results generalisable We were able to obtain reliable NPP implementation cost data. The use of mixed-effects models enabled comparisons of the MgSO 4 uptake in the pre-and post-implementation periods while allowing adjustment for known potential confounders and clustering by AHSN. As implementation of the NPP is directed by the AHSNs, unmeasured similarities and differences between units within AHSNs need to be taken into account. Our study has limitations. In a pragmatic before-and-after observational evaluation of this kind it is impossible to conclusively attribute the observed increase in uptake to the NPP alone. However, the statistical methods used in this evaluation minimise the impact of known biases and confounders, which gives reason to believe that the NPP did have a positive impact on uptake. The RCT comparing MgSO4 uptake in NPP units versus those receiving . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. enhanced support is reported separately, but results were comparable to those reported here. 13, 14 The analyses are also limited to the available data (i.e., to June 2020), it is probable that NPP benefits will persist; therefore, sustainability analyses need to be addressed in future studies. The NNRD dataset only includes records for live babies admitted to a registered neonatal unit; any baby who did not survive before admission to a neonatal unit is not recorded. In addition, the adoption dates used to demarcate the exposure periods were not firmly defined. NPP activities were reported to have started before or after the date stipulated by the AHSNs, possibly diluting the effects of the NPP on the uptake. Despite this, the various relevant sensitivity analyses did not alter the main findings. Data showed a slight decrease in uptake of MgSO 4 around April 2020, and an increase in the amount of missing MgSO 4 data at the same time. These may simply be random fluctuations but are also consistent with a possible impact of the first wave of COVID-19 in England. The two could be associated given that the staffing pressures of a pandemic are likely to affect quality of care. Also, women may have presented at hospital later during this time due to caution about contact, meaning some missed opportunities to give MgSO 4 due to imminent delivery. Further analysis of future data would be valuable to identify whether there are any trends in uptake or missing data associated with the course of the pandemic. Our study reinforces that active implementation of national initiatives utilising QI toolkits, clinical leadership, and coordinated by regional knowledge mobilis,ation teams (AHSNs) can have a substantial effect on accelerating uptake of evidence based therapies. Slow uptake comes at a clinical and economic cost with health gains foregone due to delay in the implementation of new innovations. Uptake of new evidence or guidelines is generally slow due to practical barriers, lack of knowledge and need for behaviour change. It is important to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint anticipate potential need for active implementaion to accelerate uptake and minimise this potential loss. In conclusion, the study provides evidence that this quality improvement intervention was effective and cost-effective in increasing MgSO 4 uptake in maternity units across England, and that successful national scale-up and implementation can be achieved through regional support. The NPP generated a net monetary benefit to society of approximately £3m over the 12 months following implementation, with potential to grow if MgSO4 administration rates are maintained or increased further. We would like to thank all the participants who contributed to this evaluation. We also acknowledge the support of many staff in the AHSN Network and Brent Opmeer for their support and guidance. The KL affirms that the manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We declare that the study management group have no competing financial, professional, or personal interests that might have influenced the study design or conduct. Public and Patient Involvement for this study built on the involvement work in the PReCePT pilot study. 11 This used a co-design and co-production approach including a partnership with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint BLISS, a support organisation for mothers experiencing pre-term births, and two mothers who had experienced pre-term births. These mothers were involved in study design Anonymised individual-level data for this study comes from the NNRD. Our data sharing agreement with the NNRD prohibits sharing data extracts outside of the University of Bristol research team. The NNRD data dictionary is available online 25 and copies of the Statistical Analysis Plan are available on available on the University of Bristol's institutional repository (https://research-information.bris.ac.uk/en/projects/national-precept-prevention-of-cerebralpalsy-in-pre-term-labour-). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Data missing 90 11.2% 26 5.8% 0 MgSO 4 data from records on singleton births and the first-born of multiples with records in the dataset. 1 Covers the 12 months prior to, and following the recorded NPP adoption month at each unit 2 Uptake percentages exclude missing data from the denominator. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 Crude regression of uptake post-implementation compared with pre-implementation. 2 As per model 1, plus additionally weighted on number of eligible records per unit, with robust standard errors. 3 As per model 2, plus additionally accounting for clustering by AHSN, with robust standard errors. 4 As per model 3, plus additionally adjusted for recorded start month 5 As per model 4, plus additionally adjusted for birthweight adjusted for gestational age and sex, maternal age, IMD, ethnicity, multiple birth, maternal hypertension (all unit-level aggregates), level of unit, study month . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint *We used a willingness-to-pay threshold of £20,000 per QALY . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275353 doi: medRxiv preprint Increasing Prevalence of Cerebral Palsy Among Very Preterm Infants: A Population-Based Study Cerebral Palsy-Trends in Epidemiology and Recent Development in Prenatal Mechanisms of Disease, Treatment, and Prevention Trends in the prevalence of cerebral palsy among very preterm infants (<31 weeks' gestational age) The epidemiology of cerebral palsy: Incidence, impairments and risk factors Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis Economic evaluation and cost of interventions for cerebral palsy: a systematic review Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis National Institute for Health and Care Excellence (NICE) guideline NG25. Preterm labour and birth Preventing cerebral palsy in preterm labour: a multiorganisational quality improvement approach to the adoption and spread of magnesium sulphate for neuroprotection PReCePT National Programme resources Evaluating an enhanced quality improvement intervention in maternity units: PReCePT trial protocol PReCePT Study (Prevention of cerebral palsy in pre-term labour): Evaluation Report Process evaluation in randomised controlled trials of complex interventions The UK National Neonatal Research Database: using neonatal data for research, quality improvement and more The United Kingdom National Neonatal Research Database: A validation study Framework for the treatment and reporting of missing data in observational studies: the TARMOS framework